Breaking News

You are here » Indian-Commodity  :  Corporate  :  Hindustan Copper planning to achieve turnover of Rs 10,000 crore by FY24

11-Aug2018

Hindustan Copper planning to achieve turnover of Rs 10,000 crore by FY24

Hindustan Copper is planning to achieve a turnover of Rs 10,000 crore by financial year 2023-24 through capacity expansion. Earlier this month, the company had also announced its plans to spend Rs 5,500 crore to expand its production capacity by six times from 3.6 million tonne per annum (mtpa) at present to 20 mtpa by FY24.

Hindustan Copper's principal activities include mining of copper ore, concentration of copper ore into copper concentrate through a beneficiation process and also smelting, refining and extruding of the copper concentrate into refined copper in downstream saleable products.


Related News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......